接受苯达莫司汀-利妥昔单抗治疗的老年初治套细胞淋巴瘤患者的临床参数与生物标志物评估
本研究对60岁及以上、统一接受苯达莫司汀联合利妥昔单抗治疗的初治套细胞淋巴瘤患者队列进行临床病理特征综合比较,中位生存期超过8年。结果显示s-MIPI高危(HR 3.32)、MCL35高危(HR 10.34)和母细胞样细胞学(HR 4.21)是最强预后指标,两者均高危者预后最差(HR 11.58)。作者认为MCL35联合MIPI可能有助于未来临床试验中对老年套细胞淋巴瘤患者进行风险分层。
要点
- s-MIPI高危较标危的HR为3.32(95%CI 1.65-6.68)。
- MCL35高危较标危的HR为10.34(95%CI 2.37-45.20)。
- 母细胞样细胞学较经典型的HR为4.21(95%CI 1.92-9.22)。
核心结论
- 在60岁及以上、统一接受苯达莫司汀联合利妥昔单抗治疗的初治套细胞淋巴瘤患者队列中,s-MIPI高危、MCL35高危和母细胞样细胞学是最强的预后指标。
- s-MIPI和MCL35均评为高危的患者预后最差(HR 11.58,95%CI 4.10-32.72),任一高危者预后中等但具有临床相关性(HR 2.95,95%CI 1.49-5.82)。
- 作者认为,可靠的增殖评估方法如MCL35,结合严格的细胞学评估指南和MIPI,可能是未来临床试验中对老年套细胞淋巴瘤患者进行风险分层的强有力途径。
研究设计与样本
- 研究对60岁及以上、统一接受苯达莫司汀和利妥昔单抗治疗的初治套细胞淋巴瘤患者队列进行了临床病理特征的综合比较,中位生存期超过8年。
主要发现
- s-MIPI高危较标危的HR为3.32(95%CI 1.65-6.68)。
- MCL35高危较标危的HR为10.34(95%CI 2.37-45.20)。
- 母细胞样细胞学较经典型的HR为4.21(95%CI 1.92-9.22),原文写作95% CR。
- s-MIPI和MCL35均高危者预后最差,HR为11.58(95%CI 4.10-32.72)。
- s-MIPI或MCL35任一高危者预后中等但具有临床相关性,HR为2.95(95%CI 1.49-5.82)。
临床怎么用
- 作者认为,可靠的增殖评估方法如MCL35,结合严格的套细胞淋巴瘤细胞学评估指南和MIPI,可能是未来临床试验中对老年套细胞淋巴瘤患者进行风险分层的强有力途径。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mantle cell lymphoma (MCL) is clinically and biologically heterogeneous. While various prognostic features have been proposed, none currently impact therapy selection, particularly in older patients, for whom treatment is primarily dictated by age and comorbidities. Herein, we undertook a comprehensive comparison of clinicopathological features in a cohort of patients 60 years and older, uniformly treated with bendamustine and rituximab, with a median survival of >8 years. The strongest prognostic indicators in this cohort were a high-risk call by a simplified MCL international prognostic index (s-MIPI) (HR: 3.32, 95% CI: 1.65-6.68 compared to low risk), a high-risk call by MCL35 (HR: 10.34, 95% CI: 2.37-45.20 compared to low risk) and blastoid cytology (HR: 4.21, 95% CR: 1.92-9.22 compared to classic). Patients called high risk by both the s-MIPI and MCL35 had the most dismal prognosis (HR: 11.58, 95% CI: 4.10-32.72), while those with high risk by either had a moderate but clinically relevant prognosis (HR: 2.95, 95% CI: 1.49-5.82). A robust assay to assess proliferation, such as MCL35, along with stringent guidelines for cytological evaluation of MCL, in combination with MIPI, may be a strong path to risk-stratify older MCL patients in future clinical trials.
引用
- Ramsower CA, Rosenthal A, Robetorye RS, et al. Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab. Br J Haematol. 2023. PMID: 37881141. doi:10.1111/bjh.19153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。